526
Views
5
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients?

, , &
Pages 335-340 | Received 21 Feb 2015, Accepted 20 May 2015, Published online: 28 Aug 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Roland Christian Schelker, Matthias Grube, Albrecht Reichle, Beate Wagner, Wolfgang Herr, Matthias Evert & Martin Vogelhuber. (2019) Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma. Leukemia & Lymphoma 60:9, pages 2331-2333.
Read now
Morie A. Gertz & Francis K. Buadi. (2016) Utility of immunophenotyping of plasma cells in multiple myeloma. Leukemia & Lymphoma 57:2, pages 252-253.
Read now

Articles from other publishers (3)

Yuan Jian, Zhiyao Zhang, Huixing Zhou, Guangzhong Yang, Chuanying Geng, Huijuan Wang, Wen Gao & Wenming Chen. (2022) CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14). Frontiers in Oncology 12.
Crossref
Hiroko Nishida & Taketo Yamada. (2019) Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. Journal of Oncology 2019, pages 1-10.
Crossref
Thomas Nerreter, Sebastian Letschert, Ralph Götz, Sören Doose, Sophia Danhof, Hermann Einsele, Markus Sauer & Michael Hudecek. (2019) Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature Communications 10:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.